Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261335 | 1.00 | FBP1 (0.50) | FBP1ALDH1A1KMT2ATDP1GLA | |
| SCHEMBL4261334 | 1.00 | FBP1 (0.50) | FBP1ALDH1A1KMT2ATDP1GLA | |
| SCHEMBL13232834 | 0.84 | TSHR (0.46) | ALDH1A1KMT2ATDP1POLBL3MBTL1 | |
| SCHEMBL11808459 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KMT2ATDP1POLBCA1 | |
| SCHEMBL4264328 | 0.81 | ALDH1A1 (0.40) | FBP1ALDH1A1KMT2ATDP1L3MBTL1 | |
| SCHEMBL4264331 | 0.81 | ALDH1A1 (0.40) | FBP1ALDH1A1KMT2ATDP1L3MBTL1 | |
| SCHEMBL8014956 | 0.80 | FBP1 (0.55) | FBP1ALDH1A1KMT2ATDP1TP53 | |
| SCHEMBL2801369 | 0.80 | MAPT (0.45) | ALDH1A1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL2798947 | 0.80 | EGFR (0.48) | ALDH1A1KMT2AMAPT | |
| SCHEMBL13232832 | 0.80 | EGFR (0.48) | ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3988229-A | Stabilized photopolymerizable polymeric compositions containing a photoinitiator and a nitrone derivative | EASTMAN KODAK COMPANY (US) | 1976-10-26 | — | — | US | claimed |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | WEINER, CARL P | 2009-12-24 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-6140356-A | Opthalmic pharmaceutical compositions comprising a nitrone compound and methods for treating ocular inflammation using such compositions | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5972977-A | ALPHA-(4-PYRIDYL 1-OXIDE)-N-HYDROCARBYLNITRON USEFUL FOR TREATING EYE INFLAMMATION CONDITION SUCH AS UVEITIS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| CN-1219130-A | Composition comprising a nitrone compound for use in treating ocular inflammation | CENTAUR PHARMACEUTICAL INC (US) | 1999-06-09 | — | — | CN | disclosed |
| US-3988229-A | Stabilized photopolymerizable polymeric compositions containing a photoinitiator and a nitrone derivative | EASTMAN KODAK COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | FBP1 3291/4885ALDH1A1 226/4885KMT2A 4071/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | FBP1 3291/4885ALDH1A1 226/4885KMT2A 4071/4885 |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | GPX1, SOD1, GPX4 | FBP1 1938/4885ALDH1A1 268/4885KMT2A 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.